A Trial of Observed Long-acting, Anti-HIV Treatment With a Monoclonal CCR5 Antibody (PRO 140) as an Adjunct to a New, Optimized, Oral Antiretroviral Regimen in HIV-infected Injection Drug Users With Viral Rebound and Documented Poor Adherence

This study is currently recruiting participants. (see Contacts and Locations)
Verified November 2015 by CytoDyn, Inc.
Information provided by (Responsible Party):
CytoDyn, Inc.
ClinicalTrials.gov Identifier:
First received: January 5, 2011
Last updated: November 17, 2015
Last verified: November 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: February 2017
  Estimated Primary Completion Date: January 2017 (Final data collection date for primary outcome measure)